Peptide Report
BPC + TB Peptide Report
Catalog report for BPC + TB, generated from Peptide Stacks product data and linked to the matching PeptideReports protocol page when available.
Current Price$79.00 – $119.00 CAD
Common Uses
People commonly use BPC + TB blends for injury recovery, joint and tendon support, training-related soreness, and soft-tissue repair routines where both BPC-157 and TB-500 are being considered together.
How It Works
BPC + TB combines two recovery-oriented peptide mechanisms: BPC-157 is discussed for angiogenesis, nitric-oxide, and connective-tissue signaling, while TB-500 is linked to thymosin beta-4 activity around actin regulation, cell migration, and tissue remodeling.
Storage
Powder form: In lyophilized powder form, BPC + TB is generally kept sealed, dry, protected from direct light, and refrigerated unless the product label or certificate of analysis gives different handling instructions. Avoid leaving vials in hot rooms, vehicles, direct sunlight, or other temperature swings, because moisture, heat, and light are the main storage conditions people try to control before reconstitution.
Reconstituted: After reconstitution, BPC + TB should generally be treated as more sensitive: keep it refrigerated, minimize unnecessary handling, avoid shaking, and use clean handling practices each time the vial is accessed. Follow the product label, protocol page, and any pharmacy or lab guidance for beyond-use timing; if the solution changes color, becomes cloudy, develops particles, or the vial integrity is questionable, it should not be used.
Protocol
The full BPC + TB protocol is included below. The standalone protocol page remains available if you want to open it separately.
Open Standalone Protocol
Scope
Preparation examples, syringe conversion, community-reported patterns and important limitations.
Available strengths: 10 MG and 20 MG combined
Preparation Examples
These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.
| Setup |
Diluent |
Concentration |
Unit conversion |
| 10 MG vial – 2 mL example |
Add 2 mL bacteriostatic water |
5 mg/mL |
Each U-100 unit = 50 mcg |
| 20 MG vial – 2 mL example |
Add 2 mL bacteriostatic water |
10 mg/mL |
Each U-100 unit = 100 mcg |
Syringe Conversion
| Reported amount |
10 MG setup |
20 MG setup |
| 250 mcg |
5 units |
2.5 units |
| 500 mcg |
10 units |
5 units |
| 1 mg |
20 units |
10 units |
| 2 mg |
40 units |
20 units |
Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.
Community-Reported Patterns
| Recurring report |
Frequency seen |
Context in reports |
| 250/250 mcg |
Once daily |
Lower split-component reports |
| 500/500 mcg |
Daily or intermittent |
Recovery discussions |
| 2-5 mg TB component |
Twice weekly in some reports |
Loading-style discussions |
Observations
- Community discussions most often centered on soft-tissue recovery, mobility and injury-related goals.
- The amount, frequency, route and cycle length varied substantially between reports.
- Reported outcomes were commonly confounded by diet, training, other products or existing treatment.
Caveats
- Combination-vial component amounts cannot be calculated from total vial mass unless the exact BPC-157:TB-500 ratio is confirmed on the label or COA.
- Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.